Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
NCT00280007
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
32
Enrollment
OTHER
Sponsor class
Stopped
Safety concerns in the treatment arm
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
bevacizumab
Sponsor
Medical University of Vienna